- Shamir Optical Industry Ltd.
- CABG Medical Inc.
- Cytyc Corp.
- Novacept Inc.
- Proxima Therapeutics Inc.
- Medicis Pharmaceutical Corp.
- Inamed Corp.
- Johnson & Johnson
- Guidant Corp.
- Closure Medical Corp.
- Dexcom Inc.
- Life Technologies Corp.
- Zymed Laboratories Inc.
- Dynal Biotech ASA
- DNA Research Innovations Ltd.
- Invitrogen China
- MediciNova Inc.
- Aspreva Pharmaceuticals Corp.
- Valneva USA Inc.
- Sankyo Co. Ltd.
- Daiichi Pharmaceutical Co. Ltd.
- Sumitomo Dainippon Pharma Co. Ltd.
- Sumitomo Pharmaceuticals Co. Ltd.
- Novartis AG
- Sandoz International GmbH
- Hexal AG
- Eon Labs Inc.
- Solvay SA
- Fournier Pharma
- Pfizer Inc.
- Shire PLC
- New River Pharmaceuticals Inc.
- Shamir Optical completes $42.1mm IPO
- CABG completes $31.2mm IPO
- Cytyc to acquire Novacept for $325mm
- Cytyc buys Proxima for at least $160mm
- Medicis to acquire Inamed for $2.76bn; offer withdrawn
- J&J withdraws offer to acquire Guidant
- J&J acquires Closure Medical for $370mm in cash
- DexCom completes $22.5mm Series D financing
- Invitrogen buys Zymed Labs for $60mm in cash
- Invitrogen buys Dynal Biotech for $386mm
- Invitrogen buys DNA Research Innovations for up to $65mm
- Invitrogen acquires Bio Asia for $8mm in cash
- MediciNova completes $113.4mm IPO
- Aspreva Pharmaceuticals nets $70.7mm in IPO
- Intercell raises €53.4mm with IPO
- Sankyo to buy Daiichi for $7.7bn
- Yamanouchi buys Fujisawa for $7.64bn
- Dainippon and Sumitomo Pharmaceuticals plan 2005 merger
- Novartis acquires Hexal, Eon Labs for €5.65bn
- Solvay agrees to acquire Fournier
- Pfizer licenses Coley's ProMune in potential $515mm deal
- Shire licenses New River's ADHD candidate
- Aventis to co-develop, -promote Regeneron's VEGF Trap
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.